NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Pfizer’s Mark Swindell discusses the integration of Wyeth’s vaccine business after the acquisition by Pfizer. As President of Vaccines, Mr. Swindell is helping to create a seamless process for melding the former Wyeth specialty business with Pfizer. One of the stated goals for the combined Pfizer is to become a top-tier biotherapeutics company by 2015. The company’s pipeline now includes a total of six vaccines and 27 biologics in development.